title: Correlation of adverse effects of cisplatin administration in patients affected by solid tumours: a retrospective evaluation.
abstract: Cisplatin is the most common antineoplastic drug used for the therapy of             solid tumours. To date, researchers have focused on the dosage to be administered             for each specific tumour, mainly considering the local adverse effects. The aim             of this study was to correlate the severity of the adverse effects with: i) the             dosage of cisplatin; ii) the specific site of the tumour; iii) the association             with other drugs; and iv) the symptoms. We analysed data from 123 patients with             11 different tumour classes undergoing therapy from 2007 to 2008 at St. Anna Hospital             (Ferrara, Italy), using the Spearman non-parametric correlation index. Even though             significant correlations were found among the variables, the overall results showed             that the main factor influencing the severity of the adverse effects was the dosage             of cisplatin administered.
authors: Bioacoustics Research Laboratory, Department of Neurosciences, University of Padua, I-35129 Padua, Italy. laura.astolfi@unipd.it
authors: Laura
authors: L
authors: Astolfi
authors: Sara
authors: S
authors: Ghiselli
authors: Valeria
authors: V
authors: Guaran
authors: Milvia
authors: M
authors: Chicca
authors: Edi
authors: E
authors: Simoni
authors: Elena
authors: E
authors: Olivetto
authors: Giorgio
authors: G
authors: Lelli
authors: Alessandro
authors: A
authors: Martini
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D002945:Cisplatin / Q000008:administration & dosage*; D004305:Dose-Response Relationship, Drug; D064420:Drug-Related Side Effects and Adverse Reactions / Q000209:etiology / Q000473:pathology*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009369:Neoplasms / Q000188:drug therapy* / Q000473:pathology; D012189:Retrospective Studies
chemical_list: D000970:Antineoplastic Agents; D002945:Cisplatin
references: Hear Res. 2004 Oct;196(1-2):8-18
references: 15464296
references: Lancet. 2000 Mar 25;355(9209):1075-6
references: 10744098
references: Laryngoscope. 2006 Feb;116(2):292-6
references: 16467722
references: J Clin Oncol. 2006 Jun 20;24(18):2932-47
references: 16717289
references: BMC Clin Pharmacol. 2008 Sep 17;8:7
references: 18796166
references: Int J Mol Med. 2006 Sep;18(3):511-6
references: 16865238
references: Cancer Res. 1973 Jun;33(6):1310-5
references: 4515709
references: Cancer Treat Rev. 2007 Feb;33(1):9-23
references: 17084534
references: Anticancer Drugs. 2005 Oct;16(9):1029-36
references: 16162981
references: J Bioenerg Biomembr. 2007 Feb;39(1):43-50
references: 17318397
references: Eur Arch Otorhinolaryngol. 2006 Sep;263(9):798-803
references: 16758221
references: J Thorac Oncol. 2009 Jan;4(1):119-26
references: 19096319
references: Ann N Y Acad Sci. 1999 Nov 28;884:211-25
references: 10842595
references: Br J Cancer. 1992 Aug;66(2):227-38
references: 1503895
references: Gynecol Oncol. 2007 Jun;105(3):667-71
references: 17368526
references: J Clin Oncol. 1992 May;10(5):795-803
references: 1569451
references: Ann Oncol. 2001 Jan;12(1):47-51
references: 11249048
references: Cancer Treat Rev. 2006 Aug;32(5):390-7
references: 16781082
references: J Korean Med Sci. 2007 Sep;22 Suppl:S115-21
references: 17923737
references: J Clin Oncol. 1999 Jan;17(1):409-22
references: 10458260
references: Laryngoscope. 1993 Apr;103(4 Pt 2):1-52
references: 8464301
references: Radiother Oncol. 2008 Oct;89(1):38-43
references: 18706728
references: Drugs. 2003;63(15):1565-77
references: 12887263
references: Clin Cancer Res. 1997 May;3(5):761-70
references: 9815747
references: Hear Res. 2003 Mar;177(1-2):21-31
references: 12618314
references: Neoplasia. 2007 Jan;9(1):18-22
references: 17325740
references: Curr Oncol Rep. 2005 Nov;7(6):419-34
references: 16221379
references: Pharmacotherapy. 1996 Jan-Feb;16(1):16-39
references: 8700790
references: Toxicology. 2006 May 1;222(1-2):103-13
references: 16567030
references: Cancer. 2006 Feb 15;106(4):820-9
references: 16421885
references: Mutat Res. 2001 Jul 1;478(1-2):23-43
references: 11406167
references: Eur J Med Res. 1996 Sep 20;1(11):509-14
references: 9438151
references: Semin Oncol. 2002 Feb;29(1 Suppl 3):3-14
references: 11894002
references: Acta Oncol. 2000;39(4):519-22
references: 11041115
references: J Pharm Biomed Anal. 2008 Jul 15;47(3):451-9
references: 18343619
references: Drug Discov Today. 2005 Oct 1;10(19):1313-21
references: 16214676
references: J Cell Biochem. 2007 Aug 1;101(5):1185-97
references: 17243113
references: Otolaryngol Head Neck Surg. 2007 Nov;137(5):747-52
references: 17967639
references: Eur J Cancer. 1992;28A(8-9):1358-61
references: 1515251
references: Oncologist. 2010;15 Suppl 3:3-7
references: 21036882
references: Hear Res. 1995 Aug;88(1-2):47-53
references: 8576002
references: J Clin Oncol. 2005 Jun 1;23(16):3752-9
references: 15923572
references: Curr Treat Options Oncol. 2005 May;6(3):185-93
references: 15869730
references: Audiology. 2001 Nov-Dec;40(6):327-35
references: 11781046
references: Clin Transl Oncol. 2007 Jan;9(1):40-7
references: 17272229